Visilizumab

Summary

Visilizumab (CHEMBL2108811) is a phase-3 clinical-stage antibody; indicated across 5 conditions including acute myeloid leukemia and ulcerative colitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 5 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108811
Name	Visilizumab
Type	Antibody
Max phase	3

Also known as: HUM-291, Nuvion, Visilizumab, huM291, VISILIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
ulcerative colitis	2	MONDO:0005101	EFO:0000729
Crohn disease	2	MONDO:0005011	EFO:0000384
graft versus host disease	2	MONDO:0013730	MONDO:0013730
lymphoma	1	MONDO:0005062	EFO:0000574

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE2	5
PHASE2/PHASE3	3
PHASE3	2
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00032305	PHASE2/PHASE3	COMPLETED	Research Study in Patients With Severe Ulcerative Colitis
NCT00279422	PHASE2/PHASE3	TERMINATED	A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
NCT00279435	PHASE2/PHASE3	TERMINATED	Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
NCT00502294	PHASE3	WITHDRAWN	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
NCT04722952	PHASE3	UNKNOWN	PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
NCT00032279	PHASE2	UNKNOWN	Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
NCT00032292	PHASE1/PHASE2	COMPLETED	Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
NCT00267306	PHASE1/PHASE2	COMPLETED	Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
NCT00267709	PHASE2	COMPLETED	Visilizumab for Treatment of Perianal Fistulas in Crohn’s Disease
NCT00267722	PHASE2	COMPLETED	Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn’s Disease
NCT00307827	PHASE2	TERMINATED	Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
NCT00720629	PHASE2	TERMINATED	Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
NCT00006009	PHASE1	COMPLETED	Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).